Anti-Human Amyloid-β ELISA Kit for Alzheimer's Research

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia worldwide. It affects millions of elderly individuals, leading to memory loss, cognitive decline, and ultimately, complete loss of independence. Despite decades of research, effective disease-modifying therapies have remained elusive until recently. The discovery and development of monoclonal antibodies targeting amyloid-beta (Aβ) have opened new avenues for AD treatment, with aducanumab, lecanemab, and donanemab receiving regulatory approvals. These therapeutic antibodies work by binding to aggregated forms of Aβ in the brain, promoting their clearance and reducing amyloid plaque burden. In parallel, researchers are actively studying the immune response to these therapies, as well as the natural occurrence of endogenous anti-Aβ antibodies in human subjects. The Anti-Human Amyloid-β ELISA Kit is a powerful immunoassay tool designed to detect and quantify antibodies that specifically recognize human Aβ peptides.

Figure 1.Anti-Human Amyloid-β ELISA Kit for Alzheimer's Research.

Aggregation States of Aβ

Aβ peptides exist in multiple aggregation states, each with distinct biological properties. Monomers are soluble, non-toxic forms of Aβ that are present in healthy individuals. Oligomers are small, soluble aggregates of a few Aβ molecules; these are considered the most neurotoxic species, as they can disrupt synaptic function and induce neuronal damage. Fibrils are larger, insoluble aggregates that form the structural core of amyloid plaques. Plaques are macroscopic deposits of fibrillar Aβ that are visible by microscopy and are the hallmark neuropathological feature of Alzheimer's disease. Therapeutic antibodies targeting Aβ differ in their selectivity for these aggregation states. Some antibodies recognize aggregated forms with high affinity, while others preferentially target soluble protofibrils.

Free Anti-Human Amyloid-β ELISA Kit

A specialized variant of the kit is the Free Anti-Human Amyloid-β ELISA Kit. This kit is designed to detect free (unbound) anti-Aβ antibodies in samples that may also contain soluble Aβ peptides. In biological samples, anti-Aβ antibodies can form immune complexes with endogenous Aβ. If a conventional ELISA measures total antibodies, the presence of Aβ in the sample can compete with the immobilized Aβ on the plate, leading to underestimation of total antibody levels. The Free Anti-Human Amyloid-β ELISA Kit addresses this issue by incorporating a dissociation step. The sample is treated under conditions that dissociate immune complexes without denaturing the antibodies. The dissociated free antibodies are then measured in the standard indirect ELISA format. Alternatively, the kit may use a capture format that selectively binds free antibodies. This specialized kit is particularly important for research on endogenous anti-Aβ antibodies, where the concentration of free versus bound antibody may have pathophysiological significance. For example, a high level of total anti-Aβ antibodies but low free antibody levels could indicate extensive immune complex formation, which may be associated with different clinical outcomes.

• Advantages

The Anti-Human Amyloid-β ELISA Kit offers a standardized, commercially available format that eliminates the need for in-house assay development. It is highly sensitive and specific, suitable for high-throughput screening, cost-effective compared to mass spectrometry or single-cell assays, and applicable to multiple sample types (serum, plasma, CSF). The free antibody variant addresses the important issue of sample interference by endogenous Aβ.

Amyloid-β ELISA ELISA Kits

Anti-Human beta Amyloid Antibody